Aspirin or blood thinner for preventing clots in myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study compares two daily pills, aspirin and rivaroxaban, to find which is better at preventing dangerous blood clots in people newly diagnosed with multiple myeloma who are at high risk. Participants will be randomly assigned to one of the two treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been newly diagnosed with multiple myeloma.
- You are at high risk for blood clots (a doctor will confirm this).
- You are between 18 and 90 years old.
- Your heart, liver, and kidneys are working well enough (tests will check this).
- You are not pregnant or breastfeeding, and do not have active bleeding or stomach ulcers.
- You are not already on blood thinners for other health issues.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how blood thinners are used in people with newly diagnosed multiple myeloma. The goal is to find better ways to prevent blood clots during treatment.
This study looks at how Apixaban (a blood thinner) works in people with newly diagnosed multiple myeloma. It compares them to people having knee replacement surgery. The goal is to see if the drug prevents clots effectively in both groups.
This study compares two blood-thinning medications, edoxaban and apixaban, in people who have both cancer and a blood clot. The goal is to see which one works better and is safer for preventing another clot while treating your cancer.
This trial compares aspirin versus a low-dose injectable blood thinner (LMWH) to prevent blood clots after certain orthopedic cancer surgeries. It may help lower the risk of dangerous clotting while balancing bleeding and side effects.
This trial tests whether rivaroxaban, a blood thinner pill, can help prevent dangerous blood clots in people with certain genitourinary cancers who are starting cancer treatment. It may lower clot risk, but it also has bleeding-risk tradeoffs that the study will monitor closely.
This Phase 3 study tests whether the medicine rivaroxaban can prevent dangerous blood clots in people with cancer who have a central venous catheter placed recently. It may help reduce clot risk while your catheter is in place, but you must meet safety and bleeding-risk criteria.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.